Product Images Kisqali Femara Co-pack
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 8 images provide visual information about the product associated with Kisqali Femara Co-pack NDC 0078-0909 by Novartis Pharmaceuticals Corporation, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Figure 1 Kaplan-Meier Progression Free Survival Curves – MONALEESA-2 (Intent-to-Treat Population) - figure1
This chart shows the Eventree probability percentage (%) at various censoring times (in months) for 334 individuals taking Ribociclib and 334 individuals taking a placebo. The percentages are displayed at the intervals of 100, 60, 40, and 20.*
Figure 2 Kaplan-Meier Progression Free Survival Curves – MONALEESA-7 (NSAI, Investigator Assessment) - figure2
This appears to be a table displaying data related to a study involving a cancer treatment (Rboocib) and a control group (Placsbo) over a period of two years. The table includes information regarding the number of patients at risk and the number of patients who survived at various time points during the study.*
Figure 3 Kaplan-Meier Overall Survival Curves- MONALEESA-7 (NSAI) - figure3
This appears to be a graphical representation of data from a clinical trial comparing the effectiveness of a drug called Ribocidib versus a placebo in treating an illness. The vertical axis may represent the number of patients still at risk of the illness, while the horizontal axis represents the time elapsed in months. There may have been a total of 248 patients receiving Ribocidib and 247 patients receiving the placebo in the trial. However, without more information, it is difficult to provide a detailed interpretation of the data.*
PRINCIPAL DISPLAY PANELKisqali Femara CO-PACK(ribociclib and letrozole) tablets200 mg daily dose (one 200 mg tablet) 21 Film-coated tablets2.5 mg per tablet 28 Film-coated tablets28-Day SupplyNDC 0078-0909-61Rx only - kisqali femara 01
PRINCIPAL DISPLAY PANELKisqali Femara CO-PACK(ribociclib and letrozole) tablets400 mg daily dose (two 200 mg tablets) 42 Film-coated tablets2.5 mg per tablet 28 Film-coated tablets28-Day SupplyNDC 0078-0916-61Rx only - kisqali femara 02
PRINCIPAL DISPLAY PANELKisqali Femara CO-PACK(ribociclib and letrozole) tablets600 mg daily dose (three 200 mg tablets) 63 Film-coated tablets2.5 mg per tablet 28 Film-coated tablets28-Day SupplyNDC 0078-0923-61Rx only - kisqali femara 03
letrozole structure - letrozole structure
ribociclib structure - ribociclib structure1
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.